LSE - Small Logo
LSE - Small Logo

Valentina Lichtner

January 19th, 2015

Molecular profiling for deciding therapy—the French initiative

0 comments

Estimated reading time: 5 minutes

Valentina Lichtner

January 19th, 2015

Molecular profiling for deciding therapy—the French initiative

0 comments

Estimated reading time: 5 minutes

Nowak, F., J.-C. Soria and F. Calvo (2012). “Tumour molecular profiling for deciding therapy – the French initiative.” Nat Rev Clin Oncol 9(8): 479-486. http://dx.doi.org/10.1038/nrclinonc.2012.42

From the abstract:

In France a national network of 28 regional molecular genetics centres. Selected molecular tests, free of charge, to all patients and “specific programme has also been implemented to anticipate the launch of new targeted treatments and reduce time-to-access to new drugs and experimental therapies. In 2011, 55,000 patients with cancer in France benefited from molecular predictive tests. The French nationwide initiative for tumour molecular profiling is a tool to fight inequalities in access to molecular testing and targeted therapy, and demonstrates that molecular stratification of tumours for therapeutic decisions is a cost-effective strategy that can be successfully integrated into the health-care system”.

About the author

Valentina Lichtner

Posted In: Clinical use | Medicines | Personalised medicine | Regulation | Value

Leave a Reply

Your email address will not be published. Required fields are marked *

Meta